BUZZ-Ipsen: Partner Exelixis reports positive phase II results
** Shares of French pharma co rise c. 4 pct, set for best day in 3 mo
** Ipsen partner Exelixis reports positive top-line results from Cabosun phase II trial of Cabozantinib
** In Feb., Ipsen and Exelixis signed an exclusive licensing agreement to commercialize the drug outside the U.S., Canada and Japan
** Brokerage Bryan Garnier says approval for phase III trial looks possible; lifts PT by 17 pct to EUR 63
** Stock top performer on Europe's pharma and healthcare index
© Thomson Reuters 2017 All rights reserved.